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Impaired endocytosis may represent an obstacle to gene ther- THE PROXIMAL TUBULE REPRESENTS AN
apy in polycystic kidney disease. IMPORTANT TARGET IN GENE THERAPY
Background. Autosomal-dominant polycystic kidney dis-
OF THE KIDNEYease (ADPKD) is the most common hereditary renal disease
and a frequent cause of chronic renal failure. The cloning of With a prevalence of 1:1000 [1, 2], ADPKD is the
the PKD1 and PKD2 genes, which are mutated in the great most frequent hereditary renal disease in man. Themajority of patients with this disease, opens up the opportunity
course of the disease is slowly progressive, thus leadingfor somatic gene therapy by introduction of the wild-type gene
or cDNA. Several publications have provided evidence, that to chronic renal failure in 50% of the patients at age
many portions of the nephron and the collecting duct can 60 [3–5] and contributing to 5–10% of all cases with
form cysts, including the proximal tubule. Alterations in the end-stage renal disease [6–9]. The cloning of the PKD1proximal tubule may prevent the efficient endocytosis of fil-
[10] and PKD2 [11] genes, which are mutated in far moretered proteins and thus contribute to proteinuria, a frequent
symptom in patients with polycystic kidney disease. At the than 90% of the patients with ADPKD [12, 13], has
same time this may also negatively affect various gene therapy opened up new treatment opportunities. It is now at least
strategies, since endocytosis is important for the uptake of
conceivable that a cDNA encoding the wild-type proteinforeign DNA at least under some circumstances. In the (cy/)
can be introduced into the kidneys of ADPKD patients,rat, a widely used animal model for ADPKD, cysts almost
exclusively develop from proximal tubules, and we have there- where it may functionally replace the mutated genes.
fore investigated whether proteinuria and defective endocyto- Human ADPKD can affect the collecting duct and
sis also occur in this model.
many portions of the nephron, including the proximalMethods. Proteinuria was demonstrated by direct measure-
ment and by protein gel electrophoresis of urines from 16 tubule [14–18]. A variety of different approaches, which
week-old (cy/) rats. Endocytosis was investigated by injection have already been tried to carry out renal gene therapy,
of FITC-dextran and immunohistochemical staining with anti-
have indeed resulted in the targeting of proximal tubules.ClC-5 and anti-megalin antibodies.
In the earliest publication the use of a retroviral vectorResults. Similar to the observations made in ADPKD pa-
tients, proteinuria also develops in the (cy/) rat. Using FITC- has been described [19]. This strategy, however, is severely
labeled dextran as an in vivo tracer for renal tubular endosomal limited because of the fact that retroviruses will only inte-function, we could show that portions of cyst-lining epithelia
grate into the host genome of replicating cells. Underfrom proximal tubules have lost the ability to endocytose, which
is necessary for the reabsorption of albumin and lower-molecu- normal circumstances most of the cells in the kidney are
lar-weight proteins. By immunohistochemistry the expression quiescent, but they can enter the cell cycle after an insult
of other proteins implicated in endocytosis, such as the chloride
[20]. In the study just mentioned this was achieved by thechannel ClC-5 and the albumin receptor megalin, correlated
intraperitoneal injection of folic acid [19], which leads towell with the presence and absence of FITC-dextran in cyst
wall epithelia. pronounced cell death in the proximal tubule. The surviv-
Conclusion. These data indicate that proteinuria and albu- ing cells then leave the G0-phase in order to replace theminuria in the (cy/) rat model for ADPKD are due to a loss
dead cells, thus making them accessible to retroviral geneof the endocytic machinery in epithelia of proximal tubular
cysts. Such a defect may also reduce the efficacy of certain therapy. It is obvious that retroviruses can only be used
gene therapy protocols. under very specific circumstances, which severely limits
their applicability in the setting of the kidney.
1 Present address: Division of Nephrology, Department of Medicine, In addition to retroviruses, other viruses such as ade-
University of Frankfurt/Main, Frankfurt, Germany.
novirus and adeno-associated virus have attracted a lot of
Key words: ClC-5, megalin, FITC-dextran, albuminuria, proteinuria. attention. Since adenoviruses can also transfer foreign
DNA into non-replicating cells, they are much better suited 2002 by the International Society of Nephrology
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Table 1. Total protein and albumin excretion in the urine
of 16-week-old male (cy/) and (/) rats.
(cy/) (N5) (/) (N5) P
Protein excretion [mg/24 h] 50.215.9 20.05.6 0.004a
Albumin excretion [mg/24 h] 13.16.3 3.11.3 0.022a
Data are presented as means  standard deviation.
a Statistically significant at p  0.05
for the kidney. In the first study reported, a recombinant
adenovirus was administered through the renal artery
and the ureter. While the retrograde route resulted in
prominent -galactosidase activity in the papilla, the in-
jection into the renal artery led to the infection of the
proximal tubules [21]. Similar results were published,
when cadaveric human kidneys were used. Also in this
case, reporter protein activity was predominant in the
epithelium of proximal tubules [22]. The efficiency of
recombinant adenovirus to restore a genetic defect was
finally demonstrated in the case of the aquaporin-1
knockout mouse. The water channel aquaporin-1 is
normally expressed in proximal tubules, descending thin
limbs and vasa recta, where it is important for the trans-
cellular movement of water [23–26]. Its absence in
aquaporin-1 knockout mice severely compromises the
concentrating ability of the kidney [27, 28]. When an
adenovirus encoding aquaporin-1 was injected into the
tail vein of aquaporin-1 knockout mice, a strong expres-
sion of aquaporin-1 was evident in the liver and in the
kidney. In the latter organ staining with an anti-aqua-
porin-1 antibody only resulted in the detection of aqua-
porin-1 in proximal tubules. Moreover, the concentrating
ability of the aquaporin-1 knockout mice was partially
restored [29]. Fig. 1. Location of renal cysts in the (cy/) rat model of ADPKD.
Histochemical staining of a kidney section from a (cy/) rat for alkalineOther widely applicable gene therapy protocols use
phosphatase, a marker enzyme of the proximal tubule, leads to thecationic liposomes and cationic polymers. The retro- convenient identification of proximal tubules. On this overview it can
grade injection of DNA/liposome complexes through the be easily seen that most cysts are derived from proximal tubules located
in the cortex. It is likely that the unstained cysts nevertheless haveuretero-pelvic junction can result in the expression of a
originated from proximal tubules, but have lost alkaline phosphatasereporter gene in tubular profiles, possibly proximal tu- in the course of cyst formation. Bar, 400 m.
bules [30]. Following their promising initial studies, the
same group successfully used liposomes to correct renal
nucleotides represent a very valuable option. Systemic ad-tubular acidosis in a mouse line, in which the gene coding
ministration of oligonucleotides leads to their preferential
for carbonic anhydrase II was inactivated [31]. Using accumulation in the kidney and the liver. At closer inspec-
different liposomes and an access through the renal ar- tion, it turned out that the oligonucleotides were predomi-
tery, however, another group found a rather inefficient nantly taken up by proximal tubules [34–36]. Furthermore,
expression of the reporter protein -galactosidase in the an antisense strategy also resulted in the downregulation
kidney [32, 33]. A complex between DNA and the cat- of NO-synthase type II [36] and of the sodium phosphate
ionic polymer polyethylenimine (PEI), however, yielded cotransporter [37], which demonstrates that the adminis-
a much higher transfection efficiency, and again the re- tration of antisense oligonucleotides can indeed have func-
porter protein was predominantly detected in the proxi- tional consequences.
mal tubule [32, 33].
The use of viruses, liposomes, and cationic polymers WILL DEFECTIVE ENDOCYTOSIS IN CYST
WALL EPITHELIA HINDER GENE THERAPYusually is aimed to restore or add function, but the intro-
OF POLYCYSTIC KIDNEY DISEASE?duction of an exogenous protein may sometimes be im-
possible or not desirable; rather, the ablation of a certain For all the approaches described above, i.e., adenovirus
[38, 39], adeno-associated virus [40], liposomes [41, 42],protein may be preferrable. In such a case, antisense oligo-
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Fig. 2. Endocytosis of FITC-labeled dextran by non-cystic proximal
tubules. Systemically administered FITC-labeled dextran is readily
taken up by the kidney. At a higher magnification, a punctate pattern of
FITC-dextran labeling can be seen, which represents the newly formed
endosomes in cortical proximal tubules. Bar, 25 m. Fig. 3. FITC-dextran uptake and ClC-5 protein expression in cyst-
lining epithelial cells. A cyst from a cortical kidney section of a 16
week-old (cy/) rat injected with FITC-labeled dextran shows a mosaic
distribution of FITC-dextran uptake (a). Immunofluorescence staining
with an antibody against ClC-5 (b) demonstrates that those cells, whichpolyethylenimine [43], and oligonucleotides [44, 45],
do not endocytose FITC-dextran any longer, also do not express ClC-5.
there is at least some evidence that endocytosis plays a The corresponding interference phase-contrast view is shown in c. Bar,
20 m.role in the uptake of the foreign DNA. Since cystically
transformed proximal tubules may lose their differentia-
tion markers [46], it is of great importance to determine
whether cyst wall epithelial cells derived from proximal
amounts of total protein and albumin in their urine whentubules still endocytose properly.
compared with age-matched (/) rats (Table 1). WhenProteinuria has been reported repeatedly in patients
urine samples were analyzed under non-reducing condi-with ADPKD [47–50]. So far, however, it is unclear what
tions on protein gels, we found no evidence for the excre-factors contribute to the increased urinary excretion of
tion of immunoglobulins (data not shown), which arguesproteins. In our analysis of this problem, we have turned
against a glomerular origin of proteinuria and ratherto the (cy/) rat, a model for ADPKD which closely
points to a tubular defect. This is in agreement with theresembles the human disease [46, 51–55]. Four-month-
old male (cy/) rats excreted significantly increased origin of cysts in this particular rat model, which are
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derived predominantly from proximal tubules, the neph-
ron segment with the greatest protein reabsorption ca-
pacity (Fig. 1).
Initial support for the hypothesis, that cysts suffer from
an endocytosis defect, was collected by administering
FITC-labeled dextran to (cy/) rats. As demonstrated
previously [56], FITC-dextran, which serves as an endo-
cytosis marker, was readily taken up by normal proximal
tubules (Fig. 2). We noticed, however, that some cysts
did not accumulate any FITC-dextran or showed only a
patchy reabsorption of FITC-dextran (Figs. 3a and 4a).
In order to gain further evidence for an endocytosis
defect in cyst-lining epithelial cells, we performed immu-
nohistochemistry with antibodies against the chloride
channel ClC-5 and against megalin. Proteins and pep-
tides, which pass the glomerular filtration barrier, are
effectively reabsorbed in proximal tubules. An important
first step in the reabsorption process is the binding of
albumin and other filtered proteins to receptor proteins
such as megalin [57, 58]. Subsequent to the formation
of those complexes, endosomes will form and the pro-
teins will be degraded by lysosomal proteases. The acidi-
fication of the endosomal compartment is achieved
through the action of a V-type H-ATPase, whereas
the required counterions for the imported H-ions are
probably provided by the action of the chloride channel
ClC-5 [59, 60]. The crucial role of both megalin and
ClC-5 for the reabsorption of proteins in the proximal
tubule is demonstrated by the inactivation of their re-
spective genes. A null mutation in the gene coding for
megalin leads to low-molecular-weight proteinuria in
mice [61], and patients with mutations in ClC-5 suffer
from Dent’s disease and related syndromes, which are
also characterized by massive low-molecular-weight pro-
teinuria [62, 63]. Both with the anti-ClC-5 (Fig. 3b) and
with the anti-megalin antibody (Fig. 4b), we were able
to detect cyst wall epithelia that did not express the
respective proteins any longer. The loss of megalin and
ClC-5 correlated with the absence of FITC-dextran up-
take (Figs. 3 and 4), thus corroborating the endocytosis
defect in portions of the cysts and offering an explanation
for the proteinuria.
CONCLUSIONS
Polycystic kidney disease presents an important para-
digm in the field of renal gene therapy. The cloning of
the PKD1 [10] and PKD2 [11] genes allows the clear-
tion of FITC-dextran uptake (a). Immunofluorescence staining with an
antibody against megalin (b) demonstrates that those areas, which do
Fig. 4. FITC-dextran uptake and megalin expression in cyst-lining epi- not endocytose FITC-dextran any longer, also do not express megalin.
thelial cells. Two cysts from a cortical kidney section of a 16 week-old The corresponding interference phase-contrast view is shown in c. Bar,
(cy/) rat injected with FITC-labeled dextran show a mosaic distribu- 25 m.
Witzgall et al: Endocytosis defect in polycystic kidney diseaseS-136
8. Anonymous: Incidence and causes of treated ESRD. Am J Kidneycut identification of the underlying gene defect in the
Dis 18(Suppl 2):30–37, 1991
affected patients. It should therefore in principle be pos- 9. Torra R, Darnell A, Cleries M, et al: Polycystic kidney disease
sible to introduce a wild-type cDNA into the kidneys of patients on renal replacement therapy: Data from the Catalan
renal registry. Contrib Nephrol 115:177–181, 1995patients carrying the mutated gene in order to slow down
10. The European Polycystic Kidney Disease Consortium: The po-or even prevent the development of polycystic kidneys. lycystic kidney disease 1 gene encodes a 14 kb transcript and lies
One of the challenges for a successful gene therapy will within a duplicated region on chromosome 16. Cell 77:881–894, 1994
11. Mochizuki T, Wu G, Hayashi T, et al: PKD2, a gene for polycysticlie in the efficient targeting of the various nephron seg-
kidney disease that encodes an integral membrane protein. Sciencements which, in addition to the collecting duct, can de- 272:1339–1342, 1996
velop into cysts. The proximal tubule clearly is one part 12. Peters DJM, Sandkuijl LA: Genetic heterogeneity of polycystic
kidney disease in Europe. Contrib Nephrol 97:128–139, 1992of the nephron, which is affected by ADPKD. If the
13. Wright AF, Teague PW, Pound SE, et al: A study of geneticendocytosis defect observed in the (cy/) rat model also linkage heterogeneity in 35 adult-onset polycystic kidney disease
is present in polycystic kidneys of patients, it may repre- families. Hum Genet 90:569–571, 1993
14. Baert L: Hereditary polycystic kidney disease (adult form): Asent a serious obstacle to gene therapy because of the
microdissection study of two cases at an early stage of the disease.notion that foreign DNA is taken up by the endocytic
Kidney Int 13:519–525, 1978
pathway. Therefore it would be very important to begin 15. Faraggiana T, Bernstein J, Strauss L, Churg J: Use of lec-
tins in the study of histogenesis of renal cysts. Lab Invest 53:575–early with gene therapy, when the proximal tubules as
579, 1985yet show no endocytosis defect. Other syndromes such
16. Grantham JJ, Geiser JL, Evan AP: Cyst formation and growth
as Dent’s disease, which per se are characterized by an in autosomal dominant polycystic kidney disease. Kidney Int 31:
1145–1152, 1987endocytosis defect, may require different gene therapy
17. Bachinsky DR, Sabolic I, Emmanouel DS, et al: Water channelstrategies to start with. We also want to point out that
expression in human ADPKD kidneys. Am J Physiol 268:F398–
the (cy/) rat has already been used as a model for gene F403, 1995
therapy. The administration of a recombinant adenovi- 18. Devuyst O, Burrow CR, Smith BL, et al: Expression of aqua-
porins-1 and -2 during nephrogenesis and in autosomal dominantrus into the renal artery resulted in the expression of
polycystic kidney disease. Am J Physiol 271:F169–F183, 1996the -galactosidase reporter protein in cyst wall epithelia 19. Bosch RJ, Woolf AS, Fine LG: Gene transfer into the mammalian
[64]. We would predict that those cyst-lining epithelial kidney: Direct retrovirus-transduction of regenerating tubular epi-
thelial cells. Exp Nephrol 1:49–54, 1993cells, which were infected by the adenovirus, were still
20. Witzgall R, Brown D, Schwarz C, Bonventre JV: Localizationcapable of endocytosis, but of course this assumption
of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin
has to be proven experimentally. in the post-ischemic kidney: Evidence for a heterogeneous genetic
response among nephron segments, and a large pool of mitotically
active and dedifferentiated cells. J Clin Invest 93:2175–2188, 1994ACKNOWLEDGMENTS
21. Moullier P, Friedlander G, Calise D, et al: Adenoviral-medi-
ated gene transfer to renal tubular cells in vivo. Kidney Int 45:1220–We thank Dennis Brown for his advice regarding the FITC-dextran
1225, 1994studies. The antibodies against ClC-5 and megalin were kind gifts of
22. Zeigler ST, Kerby JD, Curiel DT, et al: Molecular conjugate-Thomas Jentsch and Dontscho Kerjaschki, respectively. We are also
mediated gene transfer into isolated human kidneys. Transplanta-thankful for the superb arrangement of the figures by Rolf Nonnen-
macher and the expert photographic work of Ingrid Ertel. Jutta Chris- tion 61:812–817, 1996
tophel skillfully performed the albumin ELISAs. 23. Sabolic I, Valenti G, Verbavatz J-M, et al: Localization of the
CHIP28 water channel in rat kidney. Am J Physiol 263:C1225–
Correspondence to Dr. Ralph Witzgall, Institute for Anatomy and C1233, 1992
Cell Biology I, University of Heidelberg, Im Neuenheimer Feld 307, 24. Nielsen S, Smith BL, Christensen EI, et al: CHIP28 water chan-
69120 Heidelberg, Germany. nels are localized in constitutively water-permeable segments of
E-mail: ralph.witzgall@urz.uni-heidelberg.de the nephron. J Cell Biol 120:371–383, 1993
25. Zhang R, Skach W, Hasegawa H, et al: Cloning, functional analy-
sis and cell localization of a kidney proximal tubule water trans-REFERENCES porter homologous to CHIP28. J Cell Biol 120:359–369, 1993
26. Pallone TL, Kishore BK, Nielsen S, et al: Evidence that aqua-1. Dalgaard OZ: Bilateral polycystic disease of the kidneys: A fol-
porin-1 mediates NaCl-induced water flux across descending vasalow-up of two hundred and eighty-four patients and their families.
recta. Am J Physiol 272:F587–F596, 1997Acta Med Scand 328(Suppl):22–31, 1957
27. Ma T, Yang B, Gillespie A, et al: Severely impaired urinary2. Davies F, Coles GA, Harper PS, et al: Polycystic kidney disease
concentrating ability in transgenic mice lacking aquaporin-1 waterre-evaluated: A population-based study. Q J Med 79:477–485, 1991
channels. J Biol Chem 273:4296–4299, 19983. Churchill DN, Bear JC, Morgan J, et al: Prognosis of adult onset
28. Schnermann J, Chou C-L, Ma T, et al: Defective proximal tubularpolycystic kidney disease re-evaluated. Kidney Int 26:190–193, 1984
fluid reabsorption in transgenic aquaporin-1 null mice. Proc Natl4. Parfrey PS, Bear JC, Morgan J, et al: The diagnosis and prognosis
Acad Sci USA 95:9660–9664, 1998of autosomal dominant polycystic kidney disease. N Engl J Med
29. Yang B, Ma T, Dong J-Y, Verkman AS: Partial correction of the323:1085–1090, 1990
urinary concentrating defect in aquaporin-1 null mice by adeno-5. Gabow PA, Johnson AM, Kaehny WD, et al: Factors affecting
virus-mediated gene delivery. Hum Gene Ther 11:567–575, 2000the progression of renal disease in autosomal-dominant polycystic
30. Lai L-W, Moeckel GW, Lien Y-HH: Kidney-targeted liposome-kidney disease. Kidney Int 41:1311–1319, 1992
mediated gene transfer in mice. Gene Ther 4:426–431, 19976. Lowrie EG, Hampers CL: The success of Medicare’s end-stage
31. Lai L-W, Chan DM, Erickson RP, et al: Correction of renalrenal-disease program. N Engl J Med 305:434–438, 1981
tubular acidosis in carbonic anhydrase II-deficient mice with gene7. The European dialysis and transplant association registry:
therapy. J Clin Invest 101:1320–1325, 1998Demography of dialysis and transplantation in Europe, 1984.
Nephrol Dial Transplant 1:1–8, 1986 32. Boletta A, Benigni A, Lutz J, et al: Nonviral gene delivery to
Witzgall et al: Endocytosis defect in polycystic kidney disease S-137
the rat kidney with polyethylenimine. Hum Gene Ther 8:1243– tosomal dominant polycystic kidney disease. J Am Soc Nephrol
10:1916–1920, 19991251, 1997
33. Foglieni C, Bragonzi A, Cortese M, et al: Glomerular filtration 50. Ecder T, Chapman AB, Brosnahan GM, et al: Effect of antihyper-
tensive therapy on renal function and urinary albumin excretion inis required for transfection of proximal tubular cells in the rat
kidney following injection of DNA complexes into the renal artery. hypertensive patients with autosomal dominant polycystic kidney
disease. Am J Kidney Dis 35:427–432, 2000Gene Ther 7:279–285, 2000
34. Oberbauer R, Schreiner GF, Meyer TW: Renal uptake of an 51. Cowley BD, Jr, Gudapaty S, Kraybill AL, et al: Autosomal-
dominant polycystic kidney disease in the rat. Kidney Int 43:522–18-mer phosphorothioate oligonucleotide. Kidney Int 48:1226–
1232, 1995 534, 1993
52. Scha¨fer K, Gretz N, Bader M, et al: Characterization of the35. Rappaport J, Hanss B, Kopp JB, et al: Transport of phosphorothio-
ate oligonucleotides in kidney: Implications for molecular therapy. Han:SPRD rat model for hereditary polycystic kidney disease.
Kidney Int 46:134–152, 1994Kidney Int 47:1462–1469, 1995
36. Noiri E, Peresleni T, Miller F, Goligorsky MS: In vivo targeting 53. Gretz N, Ceccherini I, Kra¨nzlin B, et al: Gender-dependent
disease severity in autosomal polycystic kidney disease of rats.of inducible NO synthase with oligodeoxynucleotides protects rat
kidney against ischemia. J Clin Invest 97:2377–2383, 1996 Kidney Int 48:496–500, 1995
54. Cowley BD, Jr, Rupp JC, Muessel MJ, Gattone VH, II: Gen-37. Oberbauer R, Schreiner GF, Biber J, et al: In vivo suppression
of the renal Na/Pi cotransporter by antisense oligonucleotides. der and the effect of gonadal hormones on the progression of
inherited polycystic kidney disease in rats. Am J Kidney Dis 29:265–Proc Natl Acad Sci USA 93:4903–4906, 1996
38. FitzGerald DJP, Padmanabhan R, Pastan I, Willingham MC: 272, 1997
55. Kra¨nzlin B, Schieren G, Gretz N: Azotemia and extrarenalAdenovirus-induced release of epidermal growth factor and Pseu-
domonas toxin into the cytosol of KB cells during receptor-medi- manifestations in old female Han:SPRD (cy/) rats. Kidney Int
51:1160–1169, 1997ated endocytosis. Cell 32:607–617, 1983
39. Varga MJ, Weibull C, Everitt E: Infectious entry pathway of 56. Lencer WI, Weyer P, Verkman AS, et al: FITC-dextran as a probe
for endosome function and localization in kidney. Am J Physioladenovirus type 2. J Virol 65:6061–6070, 1991
40. Bartlett JS, Wilcher R, Samulski RJ: Infectious entry path- 258:C309–C317, 1990
57. Cui S, Verroust PJ, Moestrup SK, Christensen EI: Megalin/way of adeno-associated virus and adeno-associated virus vectors.
J Virol 74:2777–2785, 2000 gp330 mediates uptake of albumin in renal proximal tubule. Am
J Physiol 271:F900–F907, 199641. Zhou X, Huang L: DNA transfection mediated by cationic lipo-
somes containing lipopolylysine: Characterization and mechanism 58. Willnow TE, Goldstein JL, Orth K, et al: Low density lipopro-
tein receptor-related protein and gp330 bind similar ligands, includ-of action. Biochim Biophys Acta 1189:195–203, 1994
42. Wrobel I, Collins D: Fusion of cationic liposomes with mamma- ing plasminogen activator-inhibitor complexes and lactoferrin, an
inhibitor of chylomicron remnant clearance. J Biol Chem 267:lian cells occurs after endocytosis. Biochim Biophys Acta 1235:296–
304, 1995 26172–26180, 1992
59. Marshansky V, Bourgoin S, London˜o I, et al: Receptor-mediated43. Godbey WT, Wu KK, Mikos AG: Tracking the intracellular path
of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl endocytosis in kidney proximal tubules: Recent advances and hy-
pothesis. Electrophoresis 18:2661–2676, 1997Acad Sci USA 96:5177–5181, 1999
44. Beltinger C, Saragovi HU, Smith RM, et al: Binding, uptake, 60. Gu¨nther W, Lu¨chow A, Cluzeaud F, et al: ClC-5, the chloride
channel mutated in Dent’s disease, colocalizes with the protonand intracellular trafficking of phosphorothioate-modified oligo-
deoxynucleotides. J Clin Invest 95:1814–1823, 1995 pump in endocytotically active kidney cells. Proc Natl Acad Sci
USA 95:8075–8080, 199845. Tarraso´n G, Bellido D, Eritja R, et al: Digoxigenin-labeled
phosphorothioate oligonucleotides: A new tool for the study of 61. Nykjaer A, Dragun D, Walther D, et al: An endocytic pathway
essential for renal uptake and activation of the steroid 25-(OH)cellular uptake. Antisense Res Dev 5:193–201, 1995
46. Obermu¨ller N, Gretz N, Kriz W, et al: Differentiation and cell vitamin D3. Cell 96:507–515, 1999
62. Lloyd SE, Pearce SHS, Fisher SE, et al: A common molecu-polarity during renal cyst formation in the Han:SPRD (cy/) rat,
a model for ADPKD. Am J Physiol 273:F357–F371, 1997 lar basis for three inherited kidney stone diseases. Nature 379:445–
449, 199647. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt
proteinuria and microalbuminuria in autosomal dominant polycys- 63. Lloyd SE, Pearce SHS, Gu¨nther W, et al: Idiopathic low molecu-
lar weight proteinuria associated with hypercalciuric nephrocal-tic kidney disease. J Am Soc Nephrol 5:1349–1354, 1994
48. Sharp C, Johnson A, Gabow P: Factors relating to urinary protein cinosis in Japanese children is due to mutations of the renal chloride
channel (CLCN5). J Clin Invest 99:967–974, 1997excretion in children with autosomal dominant polycystic kidney
disease. J Am Soc Nephrol 9:1908–1914, 1998 64. Zhu G, Nicolson AG, Cowley BD, et al: In vivo adenovirus-
mediated gene transfer into normal and cystic rat kidneys. Gene49. van Dijk MA, Peters DJM, Breuning MH, Chang PC: The angio-
tensin-converting enzyme genotype and microalbuminuria in au- Ther 3:298–304, 1996
